Peptide Therapy · WOLVERINE · Serving South Metro Denver

The two peptides are studied for different but potentially complementary pathways involved in recovery. BPC-157 has generated research interest around tissue and gastrointestinal repair, while TB-500 is associated with cell migration, tissue remodeling, and blood-vessel formation.

BPC-157 is a single peptide, while Wolverine combines BPC-157 with TB-500 to target multiple pathways associated with tissue recovery and repair. The combination itself has not been established as safe or effective through large human clinical trials.

BPC-157 and TB-500 are studied for potential roles in muscle and connective-tissue recovery. Wolverine may be of interest to active individuals seeking additional recovery support, but it is not an FDA-approved treatment for exercise-related injuries.

There is no established timeline for Wolverine. Individual response may vary based on overall health, the nature of the recovery goal, activity level, formulation, and treatment protocol.

We kindly ask for at least 24 hours’ notice to cancel or reschedule your appointment. Cancellations within 24 hours will incur a 50% fee. If we arrive and are unable to reach you or access the appointment location after a brief grace period, the visit will be considered a no-show and may be charged up to the full service amount. Same-day bookings require a minimum of 4 hours’ notice for any changes. As each appointment is reserved exclusively for you — including provider time and travel — we appreciate your understanding.

Pregnancy or breastfeeding, active cancer, significant medical conditions, medication interactions, allergies, or other individual risk factors may affect candidacy. Medical evaluation is important before treatment.

By potentially supporting surrounding connective tissues and recovery processes, Wolverine may indirectly support comfortable movement and mobility. Evidence for treating specific joint conditions remains limited.

There is no established treatment timeline, and individual response can vary based on baseline skin tone, genetics, dose, and other factors. Changes in pigmentation may develop gradually rather than immediately.

Yes. Increased pigmentation does not eliminate the risk of UV-related skin damage or skin cancer. Broad-spectrum sunscreen and appropriate sun-protective measures remain important.

Melanotan II can increase pigmentation, but intentional UV exposure carries established risks and should not be considered “safe” because Melanotan II is being used. We would avoid positioning tanning beds or additional UV exposure as part of the treatment protocol.

It can increase pigmentation of existing freckles, moles, and other pigmented areas. Any new, rapidly changing, irregular, bleeding, itching, or otherwise concerning lesion should be evaluated by a qualified dermatology provider.

We kindly ask for at least 24 hours’ notice to cancel or reschedule your appointment. Cancellations within 24 hours will incur a 50% fee. If we arrive and are unable to reach you or access the appointment location after a brief grace period, the visit will be considered a no-show and may be charged up to the full service amount. Same-day bookings require a minimum of 4 hours’ notice for any changes. As each appointment is reserved exclusively for you — including provider time and travel — we appreciate your understanding.

Candidacy requires individualized medical evaluation. A history of melanoma or other skin cancers, atypical/dysplastic nevi, concerning pigmented lesions, pregnancy or breastfeeding, or certain medical conditions may make treatment inappropriate or warrant additional evaluation.

Reported effects can include nausea, flushing, decreased appetite, headache, fatigue, increased pigmentation of freckles or moles, and changes in libido or spontaneous erections. Because Melanotan II is investigational, its complete long-term safety profile has not been established.